HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men.

Abstract
Mosapride citrate, a selective agonist of the 5-hydroxytryptaine (5-HT)₄ receptor, is typically used to treat heartburn, nausea, and vomiting associated with chronic gastritis or to prepare for a barium enema X-ray examination. Mosapride citrate reportedly improves insulin sensitivity in patients with type 2 diabetes. As mosapride citrate activates the motility of the gastrointestinal tract, we hypothesized that mosapride citrate affects incretin secretion. We examined the effect of the administration of mosapride citrate on the plasma glucose, serum insulin, plasma glucagon, and plasma incretin levels before breakfast and at 60, 120, and 180 min after breakfast in men with normal glucose tolerance (NGT) or impaired glucose tolerance (IGT) to exclude gastropathy. Mosapride citrate was administered according to two different intake schedules (C: control (no drug), M: mosapride citrate 20 mg) in each of the subject groups. The area under the curve (AUC) of the plasma glucose levels was smaller in the M group than in the C group. The time profiles for the serum insulin levels at 60 and 120 min after treatment with mosapride citrate tended to be higher, although the difference was not statistically significant. The AUCs of the plasma active and total glucagon-like peptide-1 (GLP-1) levels were significantly larger in the M group than in the C group. No significant difference in the AUC of the plasma glucose-dependent insulinotropic polypeptide (GIP) level was observed between the two groups. Our results suggest that mosapride citrate may have an antidiabetic effect by increasing GLP-1 secretion.
AuthorsKazutaka Aoki, Hiroshi Kamiyama, Kiyomi Masuda, Yu Togashi, Yasuo Terauchi
JournalEndocrine journal (Endocr J) Vol. 60 Issue 4 Pg. 493-9 ( 2013) ISSN: 1348-4540 [Electronic] Japan
PMID23257734 (Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzamides
  • Blood Glucose
  • Gastrointestinal Agents
  • Hypoglycemic Agents
  • Incretins
  • Insulin
  • Morpholines
  • Serotonin 5-HT4 Receptor Agonists
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Glucagon
  • mosapride
Topics
  • Adult
  • Benzamides (therapeutic use)
  • Blood Glucose (analysis)
  • Gastric Inhibitory Polypeptide (blood, metabolism)
  • Gastrointestinal Agents (therapeutic use)
  • Gastrointestinal Tract (drug effects, metabolism)
  • Glucagon (blood)
  • Glucagon-Like Peptide 1 (blood, metabolism)
  • Glucose Intolerance (blood, drug therapy, metabolism)
  • Humans
  • Hypoglycemia (prevention & control)
  • Hypoglycemic Agents (therapeutic use)
  • Incretins (blood, metabolism)
  • Insulin (blood)
  • Male
  • Morpholines (therapeutic use)
  • Postprandial Period
  • Serotonin 5-HT4 Receptor Agonists (therapeutic use)
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: